Analysis pharmacogenomics: coronary syndromes in patients who underwent double antiplatelet aggregation, with an indication for implantation of stent

• Grant number: 09/10862-4
• Support Opportunities: Regular Research Grants
• Duration: February 01, 2010 - July 31, 2012
• Field of knowledge: Health Sciences - Medicine
• Principal Investigator: Amanda Guerra de Moraes Rego Souza
• Grantee: Amanda Guerra de Moraes Rego Souza
• Host Institution: Instituto Dante Pazzanese de Cardiologia (IDPC). Fundação Adib Jatene (FAJ). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil

Abstract

The resistance to the action of antiplatelet agents such as clopidogrel bisulphate and of acetylsalicylic acid (ASA), contributing to the unfavorable development of coronary syndrome (CS) in patients undergoing angioplasty, since the process of platelet aggregation inherently involved in its pathogenesis . In this context, this project aims to study the antiplatelet famacogenômico of the 423 patients with indication for revascularization with percutaneous coronary angioplasty and stent implantation. The patients are those with previous treatment with antiplatelet ASA (100mg/24h) and bisulphate of clopidogrel (75mg/24h) for at least 5 days before percutaneous transluminal coronary angioplasty (PTCA). Individuals with response will be considered non-responders. Plasma concentrations of antiplatelet will be determined by liquid chromatography coupled to mass spectrometry (LC-MS). The rate of aggregation will be measured using the system MultiplateTM aggregometer (Dynabyte). The global gene expression of peripheral blood leukocytes will be assessed by DNA technology microarranjos using Human Exon 1.0 ST Array (Affymetrix). Genotypic characteristics of the patients will be assessed by the system PyroMark Q24 (Qiagen). This study will contribute to the understanding of the mechanisms involved in the leukocyte response to treatment with antiplatelet and its relation to pharmacogenomics profile of patients. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

LUCHESSI, ANDRE DUCATI; CONCHEIRO, MARTA; GERMANO, JULIANA DE FREITAS; SILBIGER, VIVIAN NOGUEIRA; BORTOLIN, RAUL HERNANDES; CRUZ, ANGELINES; QUINTELA, OSCAR; BRION, MARIA; CARRACEDO, ANGEL; INIGUEZ, ANDRES; et al. ABCC3 Polymorphisms and mRNA Expression Influence the Concentration of a Carboxylic Acid Metabolite in Patients on Clopidogrel and Aspirin Therapy. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, v. 120, n. 5, p. 466-474, MAY 2017. (09/10862-4)

LUCHESSI, ANDRE DUCATI; SILBIGER, VIVIAN NOGUIEA; CRESPO HIRATA, ROSARIO DOMINGUEZ; LIMA-NETO, LIDIO GONCALVES; CAVICHIOLI, DEBORA; INIGUEZ, ANDRES; BRAVO, MARISOL; BASTOS, GUILLERMO; MORAIS REGO SOUSA, AMANDA GUERRA; BRION, MARIA; et al. Pharmacogenomics of anti-platelet therapy focused on peripheral blood cells of coronary arterial disease patients. Clinica Chimica Acta, v. 425, p. 9-17, OCT 21 2013. (09/10862-4)